上皮性卵巢癌化疗增敏的表观遗传学治疗。
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.
机构信息
Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
出版信息
Gynecol Oncol. 2010 Feb;116(2):195-201. doi: 10.1016/j.ygyno.2009.09.043. Epub 2009 Oct 24.
Abstract
Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients.
摘要
表观遗传学药物已被证明可以增强卵巢癌细胞系和动物模型中的基因表达和药物敏感性。基于有前景的临床前研究，DNA 甲基化抑制剂与现有的化疗药物联合使用有可能克服获得性耐药性，为这一特定类别的表观遗传学药物在卵巢癌临床试验中奠定了基础。最近完成的地西他滨 I 期临床试验为评估患者反应的剂量方案和生物学终点提供了重要信息。此外，表观遗传学药物对药效学靶点的影响开始显现，预测性表观遗传生物标志物和下一代表观基因组治疗药物正在开发中，以便在卵巢癌患者的临床环境中应用。
相似文献
1
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.上皮性卵巢癌化疗增敏的表观遗传学治疗。
Gynecol Oncol. 2010 Feb;116(2):195-201. doi: 10.1016/j.ygyno.2009.09.043. Epub 2009 Oct 24.
2
Epigenomics and ovarian carcinoma.表观基因组学与卵巢癌。
Biomark Med. 2010 Aug;4(4):543-70. doi: 10.2217/bmm.10.72.
3
Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.上皮性卵巢癌化疗耐药的表观遗传机制及治疗靶点
Ann Med. 2015;47(5):359-69. doi: 10.3109/07853890.2015.1043140. Epub 2015 Jul 10.
4
Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.运用表观遗传学靶向药物攻克卵巢癌耐药性。
Eur J Pharmacol. 2022 Jul 15;927:175071. doi: 10.1016/j.ejphar.2022.175071. Epub 2022 May 27.
5
Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.Fkbp1/Pax9 基因的转录表观遗传调控与卵巢癌铂类药物敏感性降低有关。
Clin Epigenetics. 2021 Aug 28;13(1):167. doi: 10.1186/s13148-021-01149-8.
6
Epigenetic therapy for ovarian cancer: promise and progress.卵巢癌的表观遗传学治疗：前景与进展。
Clin Epigenetics. 2019 Jan 15;11(1):7. doi: 10.1186/s13148-018-0602-0.
7
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.用去甲基化剂地西他滨处理的卵巢癌患者来源异种移植瘤的全基因组甲基化分析鉴定了新的表观遗传调控基因和通路。
Genome Med. 2016 Oct 20;8(1):107. doi: 10.1186/s13073-016-0361-5.
8
Epigenetics in ovarian cancer.卵巢癌中的表观遗传学
Methods Mol Biol. 2012;863:253-69. doi: 10.1007/978-1-61779-612-8_15.
9
Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.表观遗传途径为卵巢癌治疗提供靶点。
Clin Breast Cancer. 2018 Jun;18(3):189-191. doi: 10.1016/j.clbc.2017.09.009. Epub 2017 Sep 19.
10
Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a -Dependent Manner.表观遗传学疗法在卵巢癌中以依赖 - 的方式改变重复元件的表达。
Cancer Res. 2021 Oct 15;81(20):5176-5189. doi: 10.1158/0008-5472.CAN-20-4243. Epub 2021 Aug 25.
引用本文的文献
1
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations.组蛋白去乙酰化酶和多聚（ADP-核糖）聚合酶抑制剂与地西他滨在乳腺癌和卵巢癌细胞中的协同细胞毒性：对新型治疗联合的启示。
Int J Mol Sci. 2024 Aug 26;25(17):9241. doi: 10.3390/ijms25179241.
2
Sex difference in human diseases: mechanistic insights and clinical implications.人类疾病中的性别差异：机制见解与临床意义。
Signal Transduct Target Ther. 2024 Sep 10;9(1):238. doi: 10.1038/s41392-024-01929-7.
3
The Effects of Natural Epigenetic Therapies in 3D Ovarian Cancer and Patient-Derived Tumor Explants: New Avenues in Regulating the Cancer Secretome.天然表观遗传疗法对 3D 卵巢癌和患者来源肿瘤外植体的影响：调节癌症分泌组的新途径。
Biomolecules. 2023 Jul 1;13(7):1066. doi: 10.3390/biom13071066.
4
The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets.原发性乳腺肿瘤及其转移的多组学全景：扩大可操作治疗靶点的疗效。
Genes (Basel). 2022 Aug 29;13(9):1555. doi: 10.3390/genes13091555.
5
Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of Time.表观遗传学治疗在延长时间内增强经典化疗对 3D 高级别浆液性卵巢癌球体生长的抑制作用。
Biomolecules. 2021 Nov 17;11(11):1711. doi: 10.3390/biom11111711.
6
Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-κB Axis.miR-33b的表观遗传沉默通过调节TAK1/FASN/CPT1A/NF-κB轴促进卵巢癌的腹膜转移。
Cancers (Basel). 2021 Sep 24;13(19):4795. doi: 10.3390/cancers13194795.
7
Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents.二甲双胍可提高卵巢癌细胞对化疗药物的敏感性。
Oncol Lett. 2019 Sep;18(3):2404-2411. doi: 10.3892/ol.2019.10564. Epub 2019 Jul 4.
8
Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome.胰腺癌的异质性可以从基因组以外的角度来解释。
Front Oncol. 2019 Apr 5;9:246. doi: 10.3389/fonc.2019.00246. eCollection 2019.
9
Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells.双重抑制 DNA 和组蛋白甲基转移酶可增加卵巢癌细胞中的病毒模拟物。
Cancer Res. 2018 Oct 15;78(20):5754-5766. doi: 10.1158/0008-5472.CAN-17-3953. Epub 2018 Sep 5.
10
A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent.一种新型表观遗传调制剂可增强胰腺细胞对化疗药物的敏感性。
PLoS One. 2018 Jun 21;13(6):e0199130. doi: 10.1371/journal.pone.0199130. eCollection 2018.
本文引用的文献
1
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.一项地西他滨联合卡铂治疗铂类耐药复发性上皮性卵巢癌的 I 期及药效动力学研究。
Cancer. 2010 Sep 1;116(17):4043-53. doi: 10.1002/cncr.25204.
2
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.DNA甲基化与基因表达的综合分析揭示了与卵巢癌铂耐药相关的特定信号通路。
BMC Med Genomics. 2009 Jun 8;2:34. doi: 10.1186/1755-8794-2-34.
3
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.一种经合理设计的对卵巢癌具有独特抗肿瘤活性的组蛋白去乙酰化酶抑制剂。
Neoplasia. 2009 Jun;11(6):552-63, 3 p following 563. doi: 10.1593/neo.09204.
4
The biology of ovarian cancer: new opportunities for translation.卵巢癌生物学：转化医学的新机遇
Nat Rev Cancer. 2009 Jun;9(6):415-28. doi: 10.1038/nrc2644.
5
CpG islands--'a rough guide'.CpG岛——简易指南
FEBS Lett. 2009 Jun 5;583(11):1713-20. doi: 10.1016/j.febslet.2009.04.012. Epub 2009 Apr 18.
6
Methylation not a frequent "second hit" in tumors with germline BRCA mutations.胚系 BRCA 突变肿瘤中甲基化不是常见的“二次打击”。
Fam Cancer. 2009;8(4):339-46. doi: 10.1007/s10689-009-9240-1. Epub 2009 Apr 2.
7
Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.DNA甲基化和组蛋白乙酰化的联合抑制增强了体内基因的重新表达和药物敏感性。
Br J Cancer. 2009 Mar 10;100(5):758-63. doi: 10.1038/sj.bjc.6604932.
8
Beyond chemotherapy: targeted therapies in ovarian cancer.超越化疗：卵巢癌的靶向治疗
Nat Rev Cancer. 2009 Mar;9(3):167-81. doi: 10.1038/nrc2583.
9
The promises and pitfalls of epigenetic therapies in solid tumours.实体瘤表观遗传疗法的前景与陷阱
Eur J Cancer. 2009 May;45(7):1129-1136. doi: 10.1016/j.ejca.2009.01.003. Epub 2009 Feb 11.
10
Aberrant promoter methylation of SPARC in ovarian cancer.卵巢癌中SPARC基因启动子的异常甲基化
Neoplasia. 2009 Feb;11(2):126-35. doi: 10.1593/neo.81146.
Zotero 插件